Prostate Cancer Blog

/Prostate Cancer Blog/

Biopsy Slides Can Now Be Digitalized and Reviewed by Pathologists

The first whole slide imaging (WSI) system that allows for review and interpretation of digital prostate cancer pathology slides prepared from biopsied tissue has been approved by the U.S. Food and Drug Administration (FDA). Malecare is a leading advocate of second and third opinions of prostate cancer pathology from biopsy samples. The logistics of shipping and [...]

By | April 25th, 2017|Advanced Prostate Cancer|0 Comments

Blood Test Determines Effectiveness of Zytiga and or Xtandi, Before You Begin Treatment.

Adna is a new blood test that will tell you if Zytiga and Xtandi will or will not treat castration resistant prostate cancer. Imagine knowing if Zytiga and or Xtandi will fail to help you, before you spend months of time and thousands of dollars trying these drugs out. The test, called AdnaTest Prostate Cancer Panel [...]

By | April 21st, 2017|Advanced Prostate Cancer|1 Comment

HSD3B1 gene makes Androgen Deprivation Therapy (ADT) less effective

An inherited genetic change, HSD3B1 gene causes Androgen Deprivation Therapy (ADT) to be less effective for treating metastatic prostate cancer. Physician-researcher Nima Sharifi, M.D. published this finding in the October, 2016 The Lancet Oncology.  While Androgen Deprivation Therapy is effective for many men with advanced stage prostate cancer, prostate tumors eventually become resistant to ADT because the tumors make their own androgens.  “A simple blood [...]

By | April 20th, 2017|Advanced Prostate Cancer|1 Comment

A New Steroid for Treating Advanced Prostate Cancer

E4 is a steroid that may become a treatment for advanced prostate cancer, both alone and fin combination with hormone therapy. Ellen Dutman, MSc, a clinical researcher, studied E4 as a treatment to lower testosterone. “An important advantage of E4 is expected to be the avoidance of the hypoestrogenic side effects that occur with other [...]

By | April 18th, 2017|Advanced Prostate Cancer|0 Comments

Androgen Deprivation and Dementia “Might” be Linked

Androgen deprivation therapy (ADT, or, “hormone therapy”) may be linked to increased risk of having dementia. Researchers, Nead, Sinha and Nguyen reviewed nine studies by other researchers. Seven of those studies reported an adjusted effect estimate for dementia risk. That means that a majority of today’s evidence based research says that ADT and dementia probably [...]

By | April 17th, 2017|Advanced Prostate Cancer|1 Comment

Quality of Death

Quality of Death.  A new term we are introducing to the prostate cancer discussion.  Will I die in pain, agony or in some semblance of peace?   Do I want to be stupefied by opioids during my last days, hours and minutes?  Do I want to enter a coma like state?  Would I like to [...]

By | April 13th, 2017|General Information|1 Comment

Latest PSA Screening Test Guidelines from USPSTF

Here is the latest challenge to PSA test usefulness for Prostate Cancer screening in the USA.  Malecare feels you should be empowered to participate in this national health policy issue.   The U.S. Preventive Services Task Force released a new guideline, determining that the potential benefits and harms of prostate-specific antigen (PSA)-based screening in men [...]

By | April 11th, 2017|Advocacy|0 Comments

Yervoy ( Ipilimumab ) Useless When Used By Itself

Yervoy (ipilimumab) alone doesn’t help treat advanced prostate cancer patients. Yervoy activates the immune system by going after the CTLA-4 protein receptor that slows immune-system activity. But prostate cancer responds to Yervoy by increasing two other immune checkpoint molecules, PD-L1 and VISTA. And both send a don’t-eat-me signal to immune cells. That reaction is why Yerboy, by [...]

By | April 10th, 2017|Advanced Prostate Cancer|0 Comments

Selective Androgen Receptor Degraders May Become New Treatment for Castration Resistant Prostate Cancer

New molecules called selective androgen receptor degraders (SARDs) might be helpful in fighting advanced prostate cancer, according to an industry-sponsored study presented April 1, at the 99th annual meeting of the Endocrine Society. "If successful in the clinic, the novel highly potent SARDs discovered in this program could be used to treat many of the [...]

By | April 7th, 2017|Advanced Prostate Cancer|0 Comments

Estrogen As New Prostate Cancer Treatment

Fetal estrogen estetrol, also called E4, is being tested in the Netherlands as a treatment for advanced prostate cancer. "E4 for the treatment of prostate cancer would offer a new and affordable option compared to current standard and new therapies. An important advantage of E4 is expected to be the avoidance of the hypoestrogenic side [...]